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ABSTRACT 
THE TRANSSULFURATION PATHWAY SIGNIFICANTLY CONTRIBUTES TO 
GLUTATHIONE BIOSYNTHESIS IN HUMAN MAMMARY EPITHELIAL CELLS  
By Andrea Belalcázar 
Cellular methylation and antioxidant metabolism are linked by the transsulfuration pathway, 
which converts the methionine cycle intermediate homocysteine to cysteine, a precursor for 
glutathione biosynthesis, principally in hepatic cells. In mammals, the transsulfuration pathway 
has been identified in liver, kidney, pancreas and brain.  To determine whether the pathway 
exists in mammary cells human breast adenocarcinoma cells (MCF-7) and normal mammary 
epithelial cells (HMEC) were labeled with 35S-methionine for 24 hours following pre-treatment 
with a vehicle control, the cysteine biosynthesis inhibitor propargylglycine (PPG) or the 
gammaglutamyl cysteine synthesis inhibitor buthionine sulfoximine (BSO).  Cell lysates were 
prepared and reacted with glutathione-S-transferase (GST) and the fluorescent labeling 
compound monochlorobimane (mCBi) to cause glutathione (GSH) to form a fluorescent GSH-
Bimane conjugate with mCBi.   Thin layer chromatography (TLC) was used to separate 
conjugated glutathione (GSH-Bi) from the free mCBi fluor. Fluorescent images and 
autoradiography of the TLC plate were compared; incorporation of 35S-methionine into 
glutathione-bimane spots identified through fluorescence (GSH-mCBi bands) indicated that 
functional transsulfuration occurs in mammary cells (there is no other known manner for the 35S 
of methionine to incorporate into cysteine and subsequently into GSH).  Given the role that 
glutathione plays as a major cellular antioxidant, we were interested in determining the extent to 
which transsulfuration contributes to glutathione production under conditions of oxidant stress; 
enzymatic determination of the impact of PPG pre treatment and 2hr 300uM hydrogen peroxide 
treatment of HMEC’s on GSH levels indicated PPG reduced total GSH by one third, and blocked 
the ability of oxidatively stressed cells to upregulate GSH production.  In summary, results of 
this study demonstrate the presence of the transsulfuration pathway in mammary epithelial cells 
and the importance of this pathway under oxidative stress conditions. 
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INTRODUCTION 
The transsulfuration pathway (see Figure 1) links two important processes for the human body, 
the regeneration of methionine (which occurs through the methionine cycle) to form S-
adenosylmethionine, the principal cellular methyl donor, and the synthesis of glutathione, the 
principal cellular antioxidant.  The transsulfuration pathway converts homocysteine, an 
intermediate of methionine cycle, to cysteine, a biosynthesis precursor of glutathione.1  Since the 
transsulfuration pathway was first described 30 years ago by Reed and co-workers in liver, 2 it 
has also been identified in certain other tissues including the kidney, 3,4 pancreas, 5,6 intestine, 7 
lens, 8 brain, 9,10 ,11 and lymphoid cells.12  Due the vital role of glutathione against oxidative 
stress,1 we were interested in determining whether transsulfuration provides biosynthetic 
precursors for glutathione in other tissues.  Breast cancer is a highly prevalent disease, and 
oxidant stress may contribute to its development. 13  For this reason we were exploring the role of 
transsulfuration in mammary tissues.  Our hypothesis was that human mammary epithelial cells 
(HEMC) and MCF-7 human breast adenocarcinoma cells would incorporate 35S-methionine into 
glutathione via a metabolically active transsulfuration pathway.  This would indicate that a link 
exists between the methionine cycle and the synthesis of glutathione in this tissue type.  As part 
of our research strategy, two inhibitors were used, propargylglycine (PPG),14 an irreversible 
inhibitor of gamma-cystathionase, and buthionine sulfoximine (BSO), a synthetic amino acid 
that irreversibly inhibits gamma-glutamylcysteine synthetase (see Figure 2).  Propargylglycine 
inhibition thus blocks the transsulfuration pathway, preventing the genesis of cysteine by 
blocking production of its precursor, cystathionine.  Buthionine sulfoximine inhibition prevents 
the incorporation of cysteine from any source into glutathione biosynthesis. 
To be able to identify glutathione, cell pellet lysates were reacted with monochlorobimane 
(mCBi) in the presence of added glutathione s transferase (GST).  Monochlorobimane (mCBi) 
forms a stable fluorescent GSH-bimane adduct in a reaction catalyzed by GST (see Figure 3).15  
This adduct can be detected fluorimetrically permitting us to identify the location of glutathione 
as a fluorescent spot on a TLC silica plate.16  This method has been tested before using liver 
tissue,15,16 cultured neural cells,17,18,19  and ocular tissues.20 
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In the methionine cycle (see Figure 4), methionine is converted to S-adenosylmethionine (SAMe) 
in a reaction catalyzed by methionine adenosyltransferase (MAT), a magnesium dependent 
enzyme.  MAT catalyzes the only reaction that generates SAMe. 21  In this reaction methionine 
and adenosine triphosphate (ATP) combine to form SAMe, releasing the tripolyphosphate 
portion of ATP after ATP donates the adenosine group to methionine.  The remaining 
tripolyphosphate portion of ATP is hydrolyzed simultaneously to Pi and PPi by the intrinsic 
tripolyphosphatase activity of MAT. 22 
SAMe, the principal methyl donor in the human body is converted to S-Adenosylhomocysteine 
(SAH) after its methyl group has been transferred to a large variety of acceptor molecules in 
reactions catalyzed by various methyltransferases.23  These methyl groups participate in the 
methylation of DNA, RNA, proteins, membrane phospholipids and neurotransmitters.22,24  Such 
methylation plays an important role in processes such as epigenetic regulation (via DNA and 
histone methylation), protein stability, and phospholipid and neurotransmitter production.25  
Also, methylation by SAMe is a critical step in the stabilization of many proteins, including 
myelin.  SAMe is also a key metabolite that regulates hepatocyte growth, death and 
differentiation.23 
In humans, homocysteine is derived usually from methionine through the transmethylation 
pathway from the hydrolysis of SAH via a reversible reaction catalyzed by 
adenosylhomocysteinase, releasing adenosine.26  SAH is a potent competitive inhibitor of 
methylation reactions and prompt removal of adenosine and homocysteine is required to prevent 
accumulation of SAH.23  
Homocysteine has two major metabolic fates, the first is the transmethylation catalyzed by 
methionine synthase (MS) which regenerates methionine.1  MS requires normal levels of folate 
and vitamin B12, and serves to release N5-methyl tetrahydrofolate as tetrahydrofolate (THF), the 
active form of folic acid.1  Methionine regenerates by retrieving the methyl radical from 5-
methyltetrahydrofolate (5-MTHF) creating tetrahydrofolate (THF) which will then regenerate to 
5-MTHF through the action of methylentetrahydrofolate reductase (MTHFR).  This process is 
called remethylation.27,28  THF supports a number of folate dependent one carbon transfer 
reactions.  The efficiency of folate metabolism has an impact on the availability of SAMe 
because it supplies the methyl group used to regenerate methionine from homocysteine. 
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Methionine can also be synthesized from homocysteine via a zinc dependent enzyme betaine 
homocysteine methyltransferase (BHMT), which is a betaine (a metabolite of choline) dependent 
reaction which also produces dimethylglycine (see Figure 4).23  An alternative metabolite fate of 
homocysteine is the transsulfuration catalyzed by cystathionine β synthase (CBS) that converts 
homocysteine to cysteine via a cystathionine intermediate (see figure 5).1 
As a consequence of the biochemical reactions in which homocysteine is involved, a blockage in 
these pathways due to dietary deficiencies of any of the cofactors involved in methionine and 
homocysteine metabolism (folic acid, vitamin B12, vitamin B6 (pyridoxine)),26 deficiency of 
cystathionine beta-synthase (CBS), gamma-cystathionase, 5,10-methylenetetrahydrofolate 
reductase, methionine synthetase (MS) or from genetic variations, acquired pathology, toxicity, 
or nutritional inadequacy, can result in elevated levels of total homocysteine concentrations in 
plasma,26,27,28,29,30,31,32,33,34,35,36 hypermethioninemia,37,38 homocystinemia,31,37,39 
cystathioninuria,31,32,38 cirrhosis,36,40,41,42,43,44 beta-mercaptolactate cysteine disulfideuria,38 sulfite 
oxidase deficiency (SOD),38 aging,45,46 chronic renal failure,4 cancer,46,47 anemia,47 goiter,48 
impaired coagulation,49,50,51 and, hyperhomocysteinemia26,30,52,53,54 correlated with cardiovascular 
diseases, 24,30,33,34,35,45,46,52,55,56,57,58,59,60,61 neural tube defect62 and neurodegenerative disorders 
10,63,64 as Parkinson disease,46,65 Alzheimer,46,66,67 Down syndrome,46 and Autism.24,4668,69,70,71,72  
Hormonal regulation has been discovered to be also a major factor in the metabolic control of 
folate, methyl groups, and homocysteine, thereby providing a potential link between the 
pathologies associated with these pathways and hormonal imbalance.73  For example it has been 
demonstrated that CBS, one of the homocysteine-clearing enzymes, is downregulated by 
testosterone.74   
In mammals, cystathionine beta-synthase (CBS) catalyzes the first step in the transsulfuration 
pathway (see Figure 5),23 a pyridoxal 5'-phosphate (PLP)-dependent condensation of serine and 
homocysteine to cystathionine.75,76  PLP is one of the different forms of vitamin B6.77  The 
second step of the transsulfuration pathway is the hydrolysis of cystathionine to cysteine, 
ammonia, and α-ketobutyrate catalyzed by the enzyme γ-cystathionase (cystathionine-gamma-
lyase (CGL)). 
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CBS contains three functional domains. The middle domain contains the catalytic core, which is 
responsible for the pyridoxal phosphate-catalyzed reaction. The C-terminal domain contains a 
regulatory region that is responsible for allosteric activation of the enzyme by S-
adenosylmethionine. The N-terminal domain contains heme,76 and this domain regulates the 
enzyme in response to redox conditions.78  Deficiency of CBS is the major cause of inherited 
homocysteinemia. 39 
CBS is regulated by the SAMe in the liver.  When SAMe is depleted, homocysteine is channeled 
to remethylation to regenerate SAMe via MAT; whereas when SAMe is abundant, homocysteine 
is channeled to the transsulfuration pathway via CBS.23,79 
Ischemia-reperfusion injury induces a systemic inflammatory response and causes oxidative 
stress producing reactive oxygen species.80,81  Recent studies have demonstrated that ischemia-
reperfusion reduces the activity of CBS leading to homocysteine accumulation in the kidney, 
which in turn leads to increases in oxidative stress contributing to renal injury.82,83,84 
Low levels of cysteine result from a decrease in methionine levels, so cysteine synthesis can be 
sustained only if the dietary intake of methionine is adequate.24  Biosynthesis of cysteine from 
methionine via the hepatic transsulfuration pathway is impaired in some cirrhotic patients.43,44  
Cysteine, which can be derived through diet, or synthesis from homocysteine via the 
transsulfuration pathway, is the limiting substrate for the biosynthesis of glutathione.9  Cysteine 
in the presence of glutamate, γ-glutamylcysteine synthase and ATP as source of energy, is 
converted into γ-glutamylcysteine; this product is converted to glutathione via the enzyme 
glutathione synthase in the presence of glycine, and ATP as source of energy (see Figure 6).  In 
liver, approximately half of the cysteine in glutathione is derived from homocysteine via the 
transsulfuration pathway.1,2,9 
Glutathione (GSH) is a tripeptide that contains an unusual linkage between the amine group of 
cysteine and the carboxyl group of glutamate side chain. Glutathione plays an important role in 
cellular anti-oxidant defense and detoxification reactions.9  Deficits in glutathione have been 
implicated in aging and a host of diseases as reviewed by James et al.46  Glutathione (GSH) is 
also an important intravascular scavenger that protects endothelial cells from atherosclerosis.85 
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Glutathione also provides the major intracellular defense against mercury-induced neurotoxicity 
due the high affinity that mercury has for thiol groups.86 
Glutathione acts as an antioxidant when the thiol (sulfhydryl (-SH)) group of cysteine donates a 
reducing equivalent.  After glutathione (GSH) acts as an antioxidant it becomes reactive and 
forms glutathione disulfide (GSSG) combining itself with another reactive glutathione.87  
Glutathione can be regenerated through reduction from the disulfide form via the enzyme 
glutathione reductase (see Figure 7). 88,89,90 
Hydrogen peroxide is an oxidant specie that causes cellular oxidative stress.  In the methionine 
cycle the presence of a peroxide will direct homocysteine to the transsulfuration pathway, 
activating the enzyme CBS and reducing the activity of MS (see Figure 8).1 
The transsulfuration pathway, which activity is reported in a small number of tissues, plays a 
clear role in the prevention of a variety of disorders which manifest themselves when the 
pathway is deficient.  We are interested in whether transsulfuration occurs in breast tissue, to 
determine its possible role in protection versus chronic diseases of mammary tissue such as 
breast cancer.  We will test our hypothesis using human mammary epithelial cells (HEMC) and 
MCF-7 human breast adenocarcinoma cells by measuring the incorporation of 35S-methionine 
into glutathione in the presence and absence of transsulfuration and glutathione biosynthetic 
pathway inhibitors.  
  
 
 
6 
 
MATERIALS AND METHODS 
Materials.  Mammary epithelial basal medium (MEBM), HEPES buffer saline solution (HEPES-
BSS), trypsin neutralizing solution (TNS), trypsin/EDTA (0.25 mg/ml), MEGM singlequots 
(supplements and growth factors), were from Lonza (Walkersville, MD); dulbecco’s modified 
eagle’s medium (DMEM) (With 4500 mg glucose/L, 110 mg sodium pyruvate/L and L-
glutamine), dulbecco’s modified eagle’s medium (Without methionine, cystine and L-glutamine) 
(With 4500 mg glucose/L and NaHCO3), insulin from bovine pancreas,  D,L-propargylglycine, 
D,L-buthionine-(S,R)-sulfoximine (BSO), dymethyl sulfoxide (DMSO), glutathione s-transferase 
from equine liver (GST), L-methionine, L-glutathione (GSH), hydrogen peroxide 30%wt, were 
from Sigma (St. Louis, MO); fetal bovine serum (FBS) and penicillin streptomycin solution were 
from Hyclone (Logan, UT); L-[35S] methionine was from Perkin Elmer (Waltham, MA); 
monochlorobimane (mCBi) was from Invitrogen (Carlsbad, CA); potassium chloride (KCl), 
potassium phosphate monobasic (KH2PO4), sodium phosphate dibasic (Na2HPO4), butanol, 
methanol, acetic acid and scintiverse (TM) BD cocktail were from Fisher (Chicago, IL); 
trypsin/EDTA 1X (0.25% Trypsin/2.21 mM EDTA in HBSS without sodium bicarbonate, 
calcium & magnesium, porcine parvovirus tested) was from Cellgro (Manassas, VA) and sodium 
chloride (NaCl) was from Fisher (Fair Lawn, NJ). 
Cell lines.  Human mammary epithelial cells (HMEC) were purchased from Lonza (Walkersville, 
MD).  Human breast adenocarcinoma cells (MCF-7) were obtained as a gift from Dr. Michael Moore. 
Experimental protocol 1: 
The objectives of this experiment were to become familiarized with cell culture, follow  
reactions in cell culture, practice thin layer chromatography techniques, and to verify that the 
identity of the major fluorescent product present after reacting cell lysates with mCBi was the 
glutathione-bimane adduct by running mass spectroscopy. 
Cell Culture.  MCF-7 cells were cultured in T75 tissue culture flasks using water-Jacketed CO2 
incubators (Fisher Scientific, Thermo Forma Series II) at 37oC, 5% CO2 and high levels of 
humidity.  The standard medium for MCF-7 cells was Dulbecco’s Modified Eagle’s Medium 
(DMEM) with 10% fetal bovine serum (FBS), 5 ml of 200mM L-glutamine, 5 mg of insulin and 
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5 ml of penicillin.  The culture medium was changed every 3 days with 15 ml of standard 
medium. 
To prepare experimental cells, 80% confluent T75 flasks were split and used to seed a T75 flask 
with 5E6 cells in 15 ml of standard medium and incubated for 24 hours. 
Sample Collection.  Cells were harvested after 24 hours of incubation; for this purpose the 
medium was removed, the cells were rinsed twice with PBS and then trypsinized covering with 4 
ml of warm trypsin 0.25% solution (Cellgro).  When the cells detached after 5 minutes of 
incubation at 37°C and 5% CO2, they were collected in a 15 ml tube and trypsin was neutralized 
with 6 ml of a 10% FBS solution in PBS.  The 15 ml tube was centrifuged at 4oC for 10 minutes 
and the supernatant was removed from on top of the cells.  Then, the pellet was suspended with 
PBS.  Cells were pelleted again and pellets resuspended in fresh PBS, then removed to an 
eppendorf tube, spun to pellet the cells, the PBS was removed and an equal amount of water 
added to it and frozen at -80oC.  Cells were frozen and thawed 4 times with vortexing at each 
thaw.  The supernatant with cytosolic contents was isolated by spinning the cells at 4oC and 
15,000 rpm for 15 minutes in a Thermo Forma 3L GP 4500R Centrifuge and repeating the 
extraction and freeze-thaw 2 times more. 
Fluorescent labeling of GSH with monochlorobimane (mCBi).  Monochlorobimane (mCBi), in 
a reaction catalyzed by glutathione S-transferase (GST), forms a stable fluorescent GSH-bimane 
adduct that can be detected fluorimetrically and analyzed by thin layer chromatography (TLC).  
The reaction mixture to label GSH consisted of 100 µl of cell lysate, 2 µl of mCBi 20mM, 20 µl 
of 500 mM potassium phosphate (K2PO4) pH 6.5 and 2.5 µg of GST (20 µl of 25 µg GST 
dissolved in 100 µl of PBS) in a total reaction volume of 200 µl volume (water is used to 
equalize samples).  Reactions were prepared on ice then initiated by incubation at 37oC for a 
period of 10 minutes.  Reactions were stopped by freezing.  A control reaction was run by 
substituting the cell lysate with 2 µl of 10mM GSH in the same reaction volume of 200 µl.  10 µl 
of each reaction mixture were spotted on 250 microns silica gel GF uniplates (Analtech, Newark, 
DE) and analyzed by TLC using a 3:1:1 mixture of 1-butanol:methanol:water.  Two µl of 20mM 
mCBi were run in a separate lane as a control to indicate the migration of non reacted mCBi.  
The plates were removed from the TLC chamber when the mobile phase had covered 
approximately 90% of the height of the plate and allowed to air-dry [16].  Migrations of 
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fluorescent products were compared under UV light.  The fluorescence silica spots were scraped 
from the plate into a tube under an UV lamp.  Silica was extracted by adding 0.2% acetonitrile 
and extracts were sent for analysis by mass spectrometry. 
The mass spectrometer used was the Finnigan LCQ quadrupole ion trap mass spectrometer.  It is 
equipped with an atmospheric pressure ionization (API) source which can be operated in two 
modes: electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI). Both 
are soft ionization methods that can be utilized to produce either positive or negative ions. ESI is 
effective with most compounds, and is the default method of ionization. Polar compounds such 
as amines, peptides, and proteins are best ionized by ESI. Non-polar compounds such as 
hydrocarbons and steroids usually give better results with APCI. 
Experimental protocol 2: 
The objective of this experiment was to follow the incorporation of 35S-methionine into the 
glutathione biosynthetic pathway, with and without the presence of specific inhibitors in MCF-7 
cells and HMEC. 
Cell Culture and Treatment. 
MCF-7 cells were cultured as described under methods for experiment 1.  To prepare 
experimental cells, 80% confluent T75 flasks were split and used to seed 6 T75 flasks with 5E6 
cells in 15 ml of standard medium and incubated for 24 hours.  After 24 hours of incubation, 
cells received the two inhibitors added to the medium.  Two flasks were preincubated for 24 
hours with 9 mM BSO, two flasks with 2.5mM PPG and as a control, two flasks with PBS 
vehicle.  Then, to monitor the incorporation of radioactive methionine into glutathione the 
medium was replaced with 10 ml of radioactive labeling medium containing DMEM without 
methionine instead of standard DMEM, the inhibitors for each group, 0.4 mM methionine and 
35S methionine to give a 2.5 µCi/ml activity. 
HMEC are a primary cell culture and require particular conditions to ensure that they do not 
become senescent due to irreversible contact-inhibition if their confluence too greatly exceeds 
80%.  For this reason, many preliminary experiments were conducted to gain a working 
knowledge of their growth parameters (data not shown).  HMEC were cultured under the same 
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conditions of incubation as described under methods for experiment 1 but using as standard 
medium mammary epithelial basal medium (MEBM), supplemented with growth factors 
recommended by Lonza, the cell line distributor.  These are supplied in aliquots at proprietary 
concentrations, and include 2 ml of bovine pituitary extract, 0.5 ml of epidermal growth factor, 
0.5 ml of insulin, 0.5 ml of hydrocortisone and 0.5 ml of gentamicin sulfate / amphotericin-B.  
The culture medium was changed every 2 days with 15 ml of this standard medium.  To prepare 
experimental cells, 80% confluent T75 flasks were split and used to seed 12 T75 flasks each with 
2E5 cells in 15 ml of standard medium and were cultured changing the medium every 2 days.  
Seven days after seeding they were 50% confluent and experimental treatment began.  Cells 
received the two inhibitors added to the medium.  Four flasks were preincubated for 24 hours 
with 9 mM BSO, four flasks with 2.5mM PPG and as a control, four flasks with PBS.  Then, to 
monitor the incorporation of radioactive methionine into glutathione, the medium was replaced 
in 2 flasks of each group with 10 ml of radioactive labeling medium containing the appropriate 
inhibitors and 35S methionine to give a 2.5 µCi/ml activity. 
Sample Collection.  MCF-7 cells were harvested 24 hours later as described previously under 
experiment protocol 1.  HMEC are trypsinized after 48 hours of incubation; for this purpose the 
medium was removed, the cells were rinsed twice with HEPES-BSS and then trypsinized 
covering with 37°C trypsin/EDTA solution from LONZA.  When the cells were released after 6 
minutes of incubation at 37°C and 5% CO2, they were collected in a 15 ml tube neutralizing the 
trypsin with TNS and doing a final rinse of the flask with HEPES-BSS to collect residual cells.  
The 15 ml tube was centrifuged at 4oC for 10 minutes and the supernatant was removed from on 
top of the cells.  Then, the pellet was rinsed and re-suspended twice with PBS. The pellet was 
removed to an eppendorf tube, spun to pellet the cells, the PBS was removed and an equal 
amount of water added to it and frozen at -80oC.  Cells were frozen and thaw 4 times.  The 
supernatant with cytosolic contents was isolated by spinning the cells hard at 4oC and 15,000 
rpm for 15 minutes and repeating the freeze-thaw 2 times more.  Radioactive procedures were 
carried separately from non radioactive procedures to prevent radioactive cross contamination. 
Detection of GSH.  The mCBi conjugation reaction was run for this cell line as it was run for the 
MCF-7 but this time glutathione spots were fluorimetrically detected from the TLC plate using 
the BIO RAD universal hood imaging system. Radioactivity on the plates was detected through 
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phosphorimaging using the Typhoon 9200 variable mode imager, as well as by exposure to xray 
film.    
To prove the presence of glutathione in the HMEC’s that were not radioactively labeled, the 
fluorescence silica spots were scraped, silica extracted, and mass spectrometry conducted as 
described under protocol one.   
Experimental protocol 3: 
The purpose of this experiment was to determine the impact of oxidative stress on GSH 
production from transsulfuration pathway- and non transsulfuration pathway-derived cysteine as 
is shown in the flowchart in Figure 11. 
Cell Culturing and treatment.  HMEC cells were grown in T225 tissue culture flasks in 45 ml of 
standard medium, until they were 80% confluent.  The culture medium was changed every 2 
days.  
Cells were split from the flasks and 24 T225 flasks were seeded at different densities, 8 flasks 
with 2.75E6 cells, 8 with 1.38E6 cells and 8 with 7E5 cells; yielding three separate replicates at 
different harvest times.  Each of these was cultured by changing the medium every 2.  
Experiments began when cells were 50% confluent  For each group of 8 flasks, cells were treated 
for 24 hrs with either 2.5mM PPG or the vehicle control PBS.  Then, the medium was replaced 
to 4 flasks for fresh medium with inhibitors and to the other 4 flasks with oxidative stress 
medium containing 300 µM hydrogen peroxide (H2O2) and inhibitors during 2 hours. 
Pellet Collection.  The cells were harvested after the oxidative stress treatment as described 
previously for experimental protocol 2 under methods.  After the final PBS rinse, the pellets 
were roughly divided into thirds, frozen after PBS removal and stored at -80°C.  
Pellet analysis.  One aliquot of each pellet was sent to Dr. Monica Valentovic’s lab for 
determination of glutathione abundance, using their published methods.91,92,93,94,95  
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RESULTS 
Experiment 1: 
5E6 MCF-7 cells were cultured in a T75 tissue culture flask with the standard medium specified 
under methods and incubated for 24 hours, harvested, the cell pellet isolated and lysed.  A 
reaction with the cell lysate was run with monochlorobimane in the presence of GST to form 
fluorescent GSH-mCBi adducts.  As a control, the reaction was run with glutathione and 
monochlorobimane in the absence of cell pellet.  Ten µl of reaction mixture were spotted on TLC 
silica plates and allowed them to dry.  TLC was conducted using a 3:1:1 mixture of 1-
butanol:methanol:water as the mobile phase.  mCBi alone produced a single spot with fast 
migration (70 % of the height).  This matched a similar spot found in all lanes, indicating that 
sufficient mCBi was present in each sample to react with all the available GSH.  GSH-mCBi 
conjugate produced a fluorescent spot with slow migration (30% of the height).  Fluorescent 
spots were detected using a UV-lamp and lines were draw around the spots, which then, were 
scraped and eluted from silica plates for subsequent mass spectrometry analysis. 
Using a Finnigan LCQ quadrupole ion trap mass spectrometer, Dr. Frost helped us to determine 
the content of the fluorescent spots.  As result, mass spectrometry shows a peak at 498 for the 
control sample (see Figure 12) and MCF-7 lysate sample (see Figure 13) verifying the presence 
of glutathione-mCBi conjugate in the spot we had identified by virtue of its comigration with the 
GSH-mCBi control reaction products.  
Experiment 2: 
MCF-7 and HMEC cell lines were used to follow the incorporation of 35S-methionine into the 
glutathione biosynthetic pathway.  Each cell line was pretreated with two inhibitors, 2.5 mM 
propargylglycine (PPG) and 9 mM buthionine sulfoximine (BSO), in standard medium for 24 
hours; followed by replacement of the medium with radioactive labeling media, containing the 
same inhibitors and 35S-methionine  (2.5 μCi/ml) for 24 hours and 48 hours, as described under 
methods. 
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Figure 14 and Figure 15 show the digital fluorescent images of the silica plates where HMEC and 
MCF-7 cells lysates reacted with monochlorobimane were analyzed by TLC.  In these figures we 
can see that the fluorescent conjugated glutathione (GSH-mCB) was clearly separated from the 
free mCBi fluor (compare lanes 1-6 with lane 7). BSO blocks almost completely glutathione 
synthesis leading to very low GSH bimane levels, seen only as faint fluorescent spots (compare 
lanes 1 and 2 with lanes 3 and 4). Treatment with PPG inhibits the cysteine for GSH synthesis 
coming from the transsulfuration pathway, clearly a portion of, but not all glutathione present in 
the cells is derived from transsulfuration derived cysteine (compare lanes 1 and 2 with 5 and 6) 
leading to less fluorescent spots than controls, but more fluorescence than seen with BSO 
inhibition.  Glutathione can also be derived from cysteine released during protein turnover or 
imported from the extracellular medium. 
Position of the fluorescent spots from the TLC plates were marked under uv-light and TLC 
plates were scanned using a Typhoon 9200 variable mode imager, and autoradioagraphy 
conducted with Xray film.  Comparison of the positions of the fluorescent and radioactive spots 
indicate that the glutathione-bimane conjugate has incorporated 35S-methionine as is shown in 
Figure 16 and Figure 17 in lanes 1 and 2.  Incorporation of radioactivity into glutathione in BSO 
treated cells was inhibited by roughly 80%.  Interestingly, incorporation of radioactivity into 
glutathione in PPG treated cells was also inhibited by roughly 80%.  Since PPG inhibits the 
conversion of cystathionine to cysteine, this directly impacts the flux of sulphur from the 
methionine cycle.  Incorporation of 35S-methionine into glutathione (GSH-mCB bands) showed 
in the autoradiography demonstrates that functional transsulfuration occurs in mammary cells. 
The HMEC cell line was treated with inhibitors and non radioactive cell extracts were prepared 
and processed with monochlorobimane.  Extracts from GSH-mCB spots were analyzed by mass 
spectrometry.  Mass spectrometry showed a peak at 498 when cells were treated with PBS 
(vehicle) (see Figure 18) and PPG (see Figure 20) demonstrating the presence of glutathione 
migrating to the spot we identified as glutathione-bimane on the fluorescent and autoradiography 
pictures of the TLC plates (see Figure 16).  When HMECs were treated with BSO, the peak at 
498 was not detectable (see Figure 19), indicating that BSO thoroughly blocks the glutathione 
synthesis.  This is consistent with our fluorimetric findings (see Figure 16, fluorescent plate, 
comparing lanes 1 and 2 with lanes 3 and 4). 
 
 
13 
 
 
Experiment 3: 
Our objective for this experiment was to determine the impact of oxidative stress on GSH 
biosynthesis from transsulfuration pathway and also it was designed to test the hypothesis that 
transsulfuration in mammary cells provides necessary cysteine for the production of glutathione 
under conditions of oxidant stress. 
Therefore, HMEC were treated with a control or 300 µM H2O2 to induce oxidative stress 
responsive genes [93], in the presence of inhibitors and vehicle for 2 hours.  Cells were collected, 
lysates prepared, and GSH levels reported as mean +/- SEM were determined as described under 
experimental protocol 3.  Results, depicted in Figure 21 indicate that 24 hours of PPG inhibition 
reduced the levels of glutathione to roughly 2/3 that of control cells, though this was not 
determined a significant difference.  Cells treated with 300 µM H2O2 increased GSH levels 
relative to Basal controls by roughly 1/3, though this again was not determined a significant 
change.  Propargylglycine inhibited cells, when treated with 300 µM H2O2 did not increase their 
GSH levels, as compared with the increase seen with uninhibited cells (p<0.02, one way 
ANOVA).   
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DISCUSSION 
My hypothesis was that the transsulfuration pathway provides cysteine for glutathione 
production in mammary cells.  To approach testing this hypothesis I had a number of smaller 
learning objectives.  First, I needed to become familiar with general tissue culture techniques, 
followed by mastering the more exacting conditions of primary cell culture.  Cell tissue culture 
involves techniques that take time to learn and become familiarized with.  A primary cell culture 
is more stringent than the culture of transformed cells.  With a primary cell line, one has to be 
very careful with how confluent they can get and how often they are fed, to avoid triggering 
cellular senescence.  A transformed cell line is easier to handle due it ability to grow 
indifferently from frequency of media change and how much confluent they get.  I had a great 
experience using MCF-7 cell line to become familiarized with the tissue culture technique. 
My second learning objective was to learn how to conduct thin layer chromatography (TLC) 
analysis.  TLC was needed as the glutathione we isolate from cells needs to be separated and 
identified from other cell constituents.  Once we prepare cell lysates we react them with 
monochlorobimane. Reaction of glutathione instead of the cell lysates was used as a control.  
Then, we run the reaction in the presence of GST to form the fluorescent GSH-bimane 
conjugate, to identify the location of glutathione as a fluorescent spot following TLC.  Also, to 
prove the glutathione presence in the fluorescent spot, the samples were analyzed by mass 
spectrometry obtaining a peak at 498 that represents the GHS-bimane conjugate.   
My third learning objective was to master radioactivity techniques using 35S-methionine to 
determine if the methionine cycle supplies sulphur for glutathione (GSH) synthesis by the 
transsulfuration pathway.  As it name implies, the transsulfuration pathway supplies sulphur 
from the methionine cycle for glutathione synthesis.  Thus to determine if this pathway is active 
in mammary cells, we treated the MCF-7 and the HMEC cell lines with 35S-methionine.  After 
the treatments were done and the cell lysate were reacted for each cell line, we compared the 
fluorescence pictures and the autoradiographs of the TLC silica plate.  The positions and shapes 
of the fluorescent and radiographic spots on the plates were strikingly similar, indicating a co-
migration of the fluorescent label with the 35S from methionine.  These data indicate that the 35S 
from methionine did incorporate into the glutathione, demonstrating that a functional 
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transsulfuration pathway is present in human mammary epithelial cells.  Glutathione can also be 
synthesized from cysteine released during protein turnover or imported from the extracellular 
medium but the only possible way that glutathione could incorporate 35S in this experiment was 
by the transsulfuration pathway. 
When the inhibitors PPG or BSO, were used, the levels of glutathione were reduced, appearing 
as less intense spots in the TLC plate due to less incorporation of 35S methionine into glutathione 
(GSH-mCB bands).  For both inhibitor treatments, the reduction of 35S incorporation was around 
80% as each inhibits the transfer of the 35S from methionine to glutathione. 
Fluorescent levels of GSH following treatment with PPG are higher than seen following 
treatment with BSO, indicating the key difference between these inhibitors.  Propargylglycine 
blocks the formation of cysteine from cystathione, effectively blocking only the transsulfuration 
pathway as a source of cysteine.  Buthionine sulfoximine blocks the incorporation of cysteine 
from any source into the first step of glutathione biosynthesis.  This results in BSO reducing total 
GSH levels more significantly (as is shown in Figure 19 where levels were below the ability of 
the mass spec to detect), while PPG only reduces the portion of GSH that derives its cysteine 
from transsulfuration.   
When we tested whether oxidative stress would affect GSH biosynthesis using a treatment of 
H2O2, we found the following response in mammary cells.  Cells treated with 300 µM H2O2for 
two hours increased GSH synthesis by approximately ~30% as compared to untreated controls.  
In cells not treated with H2O2, PPG pre treatment for 24 hours reduced GSH by over 30%.  This 
result is similar to that which Reed and co-workers2  obtained when they treated rat hepatocytes 
with 1 mM propargylglycine for 2h; this resulted in a 35% depletion of the glutathione pool 
compared to untreated controls.  Interestingly, PPG pretreatment blocked the ability of 
mammary cells to respond to H2O2 yielding a significant reduction in GSH in PPG pretreated, 
H2O2 treated cells versus H2O2 treated cells that had received no pre treatment (One way 
ANOVA, p<0.02).  These results demonstrate the importance of the transsulfuration pathway to 
HMECs under conditions of oxidant stress.   
We feel that these experiments provide clear and conclusive evidence supporting our hypothesis, 
that the transsulfuration pathway provides cysteine for glutathione production in mammary cells.  
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Further, that this pathway is a significant source of cysteine under conditions of oxidant stress.  
These findings imply that transsulfuration may link oxidant stress to the critical methyl donor 
pool of SAMe, providing a means by which oxidant stress might impact epigenetic regulation in 
mammary tissues.  This in turn may provide a mechanism through which oxidant stress could 
lead to chronic diseases in mammary tissue such as breast cancer. 
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FIGURES 
 
 
 
Figure 1  The transsulfuration pathway linking the methionine cycle and the synthesis of glutathione.  
A metabolic pathway that converts homocysteine to cysteine, through the intermediate cystathionine. 
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Figure 2  PPG and BSO effects on the transsulfuration pathway.  Propargylglycine (PPG) is an 
irreversible inhibitor of gamma-cystathionase, and buthionine sulfoximine (BSO) is a synthetic amino 
acid that irreversibly inhibits gamma-glutamylcysteine synthetase.  While both of them prevent the 
incorporation of cysteine derived from the transsulfuration pathway into GSH, PPG has no impact on how 
cysteine derived from the media may incorporate into GSH. 
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Figure 3  Reaction scheme between monochlorobimane and glutathione to form GSH-mCB.  
Monochlorobimane (mCBi) forms a stable fluorescent GSH-bimane adduct in a reaction catalyzed by 
glutathione S-transferase (GST).  This adduct permits us to easily identify the position of GSH-bimane on 
TLC silica plates. 
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Figure 4  Methionine cycle.  Methionine is converted to S-adenosylmethionine (SAMe) by methionine 
adenosyltransferase (MAT).  SAMe is converted to S-adenosylhomocysteine (SAH) through donation of 
a methyl group by any methyltransferase.  SAH is hydrolyzed to form homocysteine via 
adenosylhomocysteinase.  Homocysteine can then regenerate methionine via methionine synthase or 
betaine homocysteine methyltransferase (BHMT), or follow the transsulfuration pathway via 
cystathionine-β-synthase (CBS) to produce cysteine (reaction not shown, see Figure 5). 
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Figure 5  Synthesis of Cysteine.  Cystathionine beta-synthase (CBS) catalyzes the first step in the 
transsulfuration pathway which converts homocysteine into cysteine in a two step reaction.  In 
the first step, cystathionine is obtained from homocysteine by a condensation reaction with serine 
in the presence of CBS.  The second step of the transsulfuration pathway is catalyzed by gamma 
cystathionase and it turns cystathionine into cysteine, ammonia and α-ketobutyrate. 
B6 
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Figure 6  Glutathione Synthesis Pathway.  Cysteine in the presence of glutamate, γ-glutamylcysteine 
synthase and ATP as source of energy, is converted into γ-glutamylcysteine; the latter is converted to 
glutathione via the enzyme glutathione synthase in the presence of glycine, and ATP as source of energy. 
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Figure 7  Role of glutathione as an antioxidant.  In the presence of an oxidative stress agent, the thiol 
group of cysteine present in glutathione donates a reducing equivalent becoming reactive and forming 
glutathione disulfide (GSSG) by combining itself with another reactive glutathione.  Then, glutathione 
can be synthesized again from the disulfide form via the enzyme glutathione reductase in the presence of 
NADPH produced in the glucose 6-phosphate dehydrogenase reaction. 
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Figure 8  Effect of H2O2 in the methionine cycle.  In the methionine cycle the presence of H2O2 will 
direct homocysteine to the transsulfuration pathway, activating the enzyme CBS and reducing the activity 
of MS.1   
 
 
  
 
 
25 
 
 
HMEC 
 
MCF-7 
  
Figure 9  The two cell lines used for studies. Pictures were taken at 400x 
magnification.  Human mammary epithelial cells (HMEC) were purchased from 
Lonza (Walkersville, MD).  Human breast adenocarcinoma cells (MCF-7) were 
obtained as a gift from Dr. Michael Moore.
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Figure 10  Methods diagram for experimental protocol 2. 
Culture cells 
Add inhibitors 
Replace medium with 
labeling medium 
Harvest cells, lyse them 
and isolate supernatant 
with cytosolic contents 
24 hours for MCF-7 
48 hours for HMEC 
Run GSH reaction with 
cell’s substrate 
24 hours 
Run TLC 
Analyze plate by 
fluorescence under UV light
Analyze spot from silica 
plate by autoradiography 
with X ray film and 
phosphor imaging system
Analyze spot from silica 
plate by mass 
spectrometry 
Non  radioactive Radioactive 
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Figure 11  Diagram of oxidative stress treatment for experiment 3.  Each replicate experiment was started 
when HMEC cells in the eight T75 flasks reached 50% confluence.  Cells were pretreated with the 
inhibitor propargylglycine (PPG) or the PBS vehicle control. Twenty four hours later they were treated 
for 2 hours with 300 μM H2O2 to generate an oxidant challenge followed by harvesting.  
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Figure 12  Mass spec of glutathione-monochlorobimane (GSH-mCB) conjugate used as a 
control. 
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Figure 13  Mass spec of MCF-7 lysate glutathione-monochlorobimane conjugate. 
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Figure 14  A scanned TLC plate showing the selectivity of the monochlorobimane reaction with 
glutathione present in HMEC lysates. 
Cells treated with PBS (lanes 1 and 2) generated glutathione-bimane (GSHmCB) conjugates 
which produced an intense fluorescent spot.  Cells treated with BSO (lanes 3 and 4) had little 
GSH-mCB conjugate, while cells treated with PPG (lanes 5 and 6) showed partial reduction of 
GSH levels, leading to less GSH-mCB conjugate.  Lane 7 indicates the migration of free mCBi 
(present in the tops of all reactions).  Inhibition of GSH levels by PPG (compare lanes 1 and 2 
with lanes 5 and 6) is an indication that transsulfuration is taking place in these cells. 
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Figure 15 A scanned TLC plate showing the selectivity of the monochlorobimane reaction with 
glutathione present in MCF-7 cell lysates. 
 
Cells treated with PBS (lanes 1 and 2) generated glutathione-bimane (GSHmCB) conjugates 
which produced an intense fluorescent spot.  Cells treated with BSO (lanes 3 and 4) had little 
GSH-mCB conjugate, while cells treated with PPG (lanes 5 and 6) showed partial reduction of 
GSH levels, leading to less GSH-mCB conjugate.  Lane 7 indicates the migration of free mCBi 
(present in the tops of all reactions).  Inhibition of GSH levels by PPG (compare lanes 1 and 2 
with lanes 5 and 6) is an indication that transsulfuration is taking place in these cells. 
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Figure 16  Incorporation of 35S-methionine into glutathione (GSH-mCB bands) showed in the 
autoradiography demonstrates that functional transsulfuration occurs in HMEC. 
 
HMEC cells treated with PBS (lanes 1 and 2) that generated glutathione-bimane (GSHmCB) 
conjugates producing an intense fluorescent spot also incorporated 35S-methionine represented as 
a darker spot in the autoradiography.  Cells treated with BSO (lanes 3 and 4) and with PPG 
(lanes 5 and 6) that had less GSH-mCB conjugate than controls, also show less incorporation of 
35S-methionine.  Incorporation of 35S-methionine in controls (lanes 1 and 2) demonstrates that 
functional transsulfuration occurs in mammary cells. 
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Figure 17  Incorporation of 35S-methionine into glutathione (GSH-mCB bands) showed in the 
autoradiography demonstrates that functional transsulfuration occurs in MCF-7. 
 
MCF-7 cells treated with PBS (lanes 1 and 2) that generated glutathione-bimane (GSHmCB) 
conjugates producing an intense fluorescent spot also incorporated 35S-methionine represented as 
a darker spot in the autoradiography.  Cells treated with BSO (lanes 3 and 4) and with PPG 
(lanes 5 and 6) that had less GSH-mCB conjugate than controls, also show less incorporation of 
35S-methionine.  Incorporation of 35S-methionine in controls (lanes 1 and 2) demonstrates that 
functional transsulfuration occurs in mammary cells. 
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Figure 18  Mass spec of HMEC showing the glutathione-monochlorobimane conjugate peak. 
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Figure 19  Mass spec of HMEC showing that under the presence of BSO there is no presence of 
glutathione-monochlorobimane conjugate peak.  
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Figure 20  Mass spec of HMEC treated with PPG showing the peak at 498 for glutathione-
monochlorobimane conjugate (GSH-mCB).  Indicates that under the presence of PPG, glutathione can be 
still synthesized as shown in the fluorescent and autoradiography figure of the TLC plate. 
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Figure 21  Impact of transsulfuration inhibition with PPG on cellular total glutathione levels in HMEC 
subjected to oxidative challenge (H2O2). 
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APPENDIX 
 
List of abbreviations 
 
ATP Adenosine Triphosphate  
BHMT Betaine Homocysteine Methyltransferase 
BSO Buthionine Sulfoximine  
CBS Cystathionine β Synthase  
DMEM Dulbecco’s Modified Eagle’s Medium  
DMSO Dimethyl Sulfoxide  
FBS Fetal Bovine Serum 
GSH Glutathione 
GST Glutathione-S-Transferase  
HEPES-BSS HEPES Buffered Saline Solution  
MCF-7 Human breast adenocarcinoma cells  
MEBM Mammary Epithelial Basal Medium  
MAT Methionine Adenosyltransferase  
MS Methionine Synthase  
mCBi Monochlorobimane 
HMEC Human mammary epithelial cells 
PBS Phosphate Buffered Saline  
PPG Propargylglycine 
SAH S-Adenosylhomocysteine 
SAMe S-adenosylmethionine  
THF Tetrahydrofolate 
TLC Thin Layer Chromatography  
TNS Trypsin Neutralizing Solution  
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